Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Image showing a patient smiling and holding a photo
Anoro Ellipta has demonstrated superior lung function improvement (trough FEV1) vs. another LAMA/LABA1



This is a fictional patient for illustrative purposes.

Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

When your COPD patients struggle with breathlessness, your choice of LAMA/LABA maintenance therapy could make a difference.

Explore Anoro Ellipta’s data vs. Spiolto Respimat and vs. Bevespi Aerosphere

Anoro Ellipta vs. Spiolto Respimat1

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation), Anoro Ellipta demonstrated a 1.4x superior lung function improvement vs. Spiolto Respimat (with an extra 52mL improvement in trough FEV1)1

Trough FEV1 at week 8 in adults with moderate COPD* (ITT population)1

Graph demonstrating a 52mL improvement in lung function Image demonstrating an 52mL improvement in lung function

*Post bronchodilator FEV1 ≤70% to ≥50% predicted, mMRC ≥2;1
ITT, intention to treat; LS, least squares; MCID (minimum clinically important difference) = 100mL

Adapted from Feldman et al. 20171

  • Feldman et al. 2017 study details

    An 8-week, randomised, open-label, non-inferiority, two-period crossover study in symptomatic patients with moderate COPD not on maintenance therapy for ≥2 weeks prior to randomisation. Patients had CAT≥10, mMRC≥2 and post-bronchodilator FEV1 of ≥ 50 to ≤ 70% predicted normal. Primary endpoint: change from baseline in trough FEV1 at Week 8 (assessed for non-inferiority using a non-inferiority margin of -50mL; followed by superiority).1

    Anoro Ellipta was well tolerated, with a comparable safety profile to Spiolto Respimat1

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation), Anoro Ellipta reduced rescue medication use by an extra 38% vs. Spiolto Respimat (difference: 0.25 puffs/day)1

Change in rescue medication use (Weeks 1-8, ITT population)1

Image demonstrating a 38% reduction in rescue medication use Inhaler icon

ITT, intention to treat; LS, least squares; 

Adapted from Feldman et al. 20171

  • Feldman et al. 2017 study details

    An 8-week, randomised, open-label, non-inferiority, two-period crossover study in symptomatic patients with moderate COPD not on maintenance therapy for ≥2 weeks prior to randomisation. Patients had CAT≥10, mMRC≥2 and post-bronchodilator FEV1 of ≥ 50 to ≤ 70% predicted normal. Primary endpoint: change from baseline in trough FEV1 at Week 8 (assessed for non-inferiority using a non-inferiority margin of -50mL; followed by superiority).1

    Anoro Ellipta was well tolerated, with a comparable safety profile to Spiolto Respimat1

Anoro Ellipta vs. Bevespi Aerosphere2

In a 24-week, non-inferiority study of Bevespi Aerosphere vs. Anoro Ellipta in moderate-to-very severe COPD patients, Anoro Ellipta demonstrated an extra 84mL improvement in trough FEV1 from baseline (co-primary endpoint), while improvement in peak FEV1 within 2 hours post-dose (co-primary endpoint) was similar for both medicines (difference: 3mL)2

  • Click to see the trough FEV1 data

    Change from baseline in trough FEV1 at 24 weeks (full set analysis)2

    Image demonstrating a 84mL improvement in lung function Image demonstrating a 84mL improvement in lung function

    For the per protocol analysis, the results were 170mL for Anoro (n=489) vs. 82mL for Bevespi (n=474): difference 87mL (97.5% CI: -117, -57). Non-inferiority margin: -50mL.
    MCID, minimum clinically important difference = 100mL; LS, Least Squares

    Adapted from Maltais et al. 20192

  • Maltais et al. 2019 study details

    AERISTO was a Phase lllb randomised, double-blind, double-dummy, multicentre, parallel-group, 24-week non-inferiority study comparing Bevespi Aerosphere 9/4.8mcg (two inhalations BD) vs. Anoro Ellipta (one inhalation OD) in patients with moderate-to-very severe COPD. Patients had CAT≥10, FEV1/FVC ratio <70% and post-bronchodilator FEV1 <80% predicted normal value. Primary endpoints: change from baseline in morning pre-dose trough FEV1 (assessed for non-inferiority using a non-inferiority margin of -50mL) and peak change from baseline in FEV1 within 2h post-dose (assessed for non-inferiority using non-inferiority margin of -50mL; followed by superiority) over 24 weeks. Bevespi Aerosphere was non-inferior to Anoro Ellipta for the co-primary endpoint of peak FEV1 (but not superior). For the co-primary endpoint of trough FEV1, Bevespi Aerosphere did not demonstrate non-inferiority to Anoro Ellipta.2

    Anoro Ellipta was well tolerated, with a comparable safety profile to Bevespi Aerosphere2

Get started with Anoro Ellipta

Order demo device

PATIENT RESOURCES

You might also be interested in…

Dosing & the Ellipta device

NICE COPD Guidelines

Molecules

Head-to-head data vs. a LAMA

References

  1. Feldman G.J et al. Adv Ther 2017; 34:2518–2533
  2. Maltais F et al. Adv Ther 2019; 36:2434–2449.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

PM-GB-UCV-WCNT-200038 May 2021